PT  - JOURNAL ARTICLE
AU  - Mototsugu Kato
AU  - Noriko Ito
AU  - Mamiko Demura
AU  - Kimitoshi Kubo
AU  - Katsuhiro Mabe
AU  - Naohiko Harada
TI  - Study for every other day administration of vonoprazan in maintenance treatment of erosive GERD: study protocol for a multicentre randomised cross-over study
AID  - 10.1136/bmjgast-2017-000197
DP  - 2018 Feb 01
TA  - BMJ Open Gastroenterology
PG  - e000197
VI  - 5
IP  - 1
4099  - http://bmjopengastro.bmj.com//content/5/1/e000197.short
4100  - http://bmjopengastro.bmj.com//content/5/1/e000197.full
AB  - Introduction The first drug selected for treatment of gastro-oesophageal reflux disease (GERD) and prevention of the recurrence is a proton pump inhibitor (PPI), but recently, a potassium-competitive acid blocker (P-CAB) was put on the market in Japan. Its onset of effect is faster than PPI, and it takes more than 2 days to recover acid secretion after the withdrawal period. Therefore, unlike PPI, the usefulness of every other day administration or discontinuous administration is expected.Methods and analysis This study is a prospective, multicentre, open-label, two-period randomised cross-over study to compare the efficacy and safety of PPI every other day administration and P-CAB every other day administration in 120 patients who receive erosive GERD maintenance therapy with PPI. Patients will be randomly allocated to receive 4 weeks P-CAB or PPI followed by 4 weeks cross over, where those on P-CAB will receive PPI and vice versa. The primary endpoint is proportion of asymptomatic patients. Secondary endpoints are suppressive effect of GERD symptoms, proportion of asymptomatic patients at each time point, safety and cost-saving effect of P-CAB every other day administration, compliance with every other day administration, and proportion of asymptomatic patients at the first month of study drug administration.Ethics and dissemination This study was approved by the National Hospital Organization Central Review Board for Clinical Trials (5 December 2017).Discussion If P-CAB every other day administration is established as one of GERD maintenance therapies, there is merit in both medical cost reduction and the safety to alleviate elevation in serum gastrin.Trial registration number UMIN000034701.